Familial antithrombin III deficiency and its clinical significance

Nakagawa, Masao; Tsuji, Hajime; Kawamura, Tsunehiro; Okajima, Yasushi; Drano, Sumio; Okuda, Seisuke; Nishizawa, Akihiko; Kitani, Teruo; Watada, Mitsuro; Ijichi, Hamao

doi:10.2491/jjsth1970.11.106

Cited by 12 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many patients with hereditary thrombophilia treated with oral anticoagulants have an increase in antithrombin III levels. 34,68,78 How- ever, there have also been patients reported to be unresponsive to oral anticoagulant therapy and demonstrate no significant increase in antithrombin III levels. 48,62,80 One individual in the hereditary thrombophilia family presented in Table 2 was treated with oral anticoagulants and two were treated with combination platelet suppressive therapy (aspirin and dipyridamole); the rises in antithrombin III levels were identical.…”

Section: Hereditary Deficiency Of Antithrombin III (Hereditary Thrombmentioning

confidence: 99%

Clinical Relevance of Antithrombin III

Bick¹

1982

Semin Thromb Hemost

141

View full text Add to dashboard Cite

Many unrelated clinical conditions that are associated with significant decreases in antithrombin III have been summarized. In addition, prospects for future therapy with antithrombin III concentrates have been discussed. The clinical indications for antithrombin III determinations, including the reasons for performing the assay and those specific patient populations subjected to antithrombin III assays in this author's clinical practice, have been outlined. It is to be anticipated that with the new general availability of simple reliable antithrombin III assay systems using synthetic substrates that more and more populations will be adequately studied and clinical indications for the use of antithrombin III determinations and concentrates may become more firm or may change.

show abstract